Colleen M Niswender Selected Research

metabotropic glutamate receptor 4

1/2016	Discovery, Synthesis, and Preclinical Characterization of N-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4).
1/2016	Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers.
8/2015	Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
6/2009	mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease.
1/2009	Recent progress in the development of mGluR4 positive allosteric modulators for the treatment of Parkinson's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Colleen M Niswender Research Topics

Disease

32	Schizophrenia (Dementia Praecox) 01/2022 - 03/2009
21	Parkinson Disease (Parkinson's Disease) 08/2021 - 01/2009
12	Alzheimer Disease (Alzheimer's Disease) 12/2019 - 03/2009
10	Catalepsy 01/2021 - 11/2008
8	Rett Syndrome (Rett's Disorder) 01/2022 - 01/2017
8	Neurodevelopmental Disorders 01/2022 - 01/2017
6	Central Nervous System Diseases (CNS Diseases) 08/2021 - 07/2007
4	Seizures (Absence Seizure) 01/2019 - 08/2009
3	Brain Diseases (Brain Disorder) 01/2018 - 02/2015
3	Dyskinesias (Dyskinesia) 01/2016 - 12/2009
2	Lubs X-linked mental retardation syndrome 01/2022 - 01/2018
2	Dystonia (Limb Dystonia) 08/2021 - 08/2009
2	Mental Disorders (Mental Disorder) 01/2018 - 01/2010
2	Cocaine-Related Disorders (Cocaine Addiction) 03/2016 - 08/2013
2	Fragile X Syndrome (Martin Bell Syndrome) 01/2016 - 09/2012
2	Autistic Disorder (Autism) 01/2016 - 09/2012
2	Bipolar Disorder (Manic Depressive Psychosis) 11/2015 - 01/2015
2	Psychotic Disorders (Schizoaffective Disorder) 03/2015 - 07/2014
1	Memory Disorders (Memory Loss) 01/2022
1	Opioid-Related Disorders (Opiate Addiction) 01/2022
1	Apnea 01/2022
1	Mood Disorders (Mood Disorder) 11/2021
1	Movement Disorders (Movement Disorder) 08/2021
1	Neurobehavioral Manifestations 01/2018
1	Syndrome (Syndromes) 01/2017
1	Substance-Related Disorders (Drug Abuse) 03/2016
1	Nervous System Diseases (Neurological Disorders) 01/2016
1	Inflammation (Inflammations) 01/2016
1	Communicable Diseases (Infectious Diseases) 08/2013
1	Disease Progression 12/2009
1	Microphthalmos 02/2008

Drug/Important Bio-Agent (IBA)

18	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 01/2022 - 07/2007
17	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 01/2022 - 01/2008
10	Haloperidol (Haldol)FDA LinkGeneric 01/2021 - 11/2008
7	Pharmaceutical PreparationsIBA 01/2018 - 01/2010
5	Methyl-CpG-Binding Protein 2IBA 01/2022 - 01/2017
5	metabotropic glutamate receptor 7IBA 01/2021 - 03/2010
5	metabotropic glutamate receptor 4IBA 01/2016 - 01/2009
4	Cholinergic Agents (Cholinergics)IBA 01/2022 - 09/2016
4	Glutamate Receptors (Glutamate Receptor)IBA 12/2016 - 12/2009
4	Metabotropic Glutamate 5 ReceptorIBA 03/2016 - 10/2013
4	Levodopa (L Dopa)FDA LinkGeneric 01/2016 - 12/2009
3	Dizocilpine Maleate (Dizocilpine)IBA 01/2022 - 03/2016
3	Glutamic Acid (Glutamate)FDA Link 11/2021 - 07/2014
3	N-Methylaspartate (NMDA)IBA 12/2016 - 05/2015
2	gamma-Aminobutyric Acid (GABA)IBA 01/2022 - 08/2015
2	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2022 - 11/2021
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2022 - 12/2009
2	Antipsychotic Agents (Antipsychotics)IBA 01/2022 - 09/2016
2	benzocycloheptapyridineIBA 01/2018 - 01/2013
2	metabotropic glutamate receptor 2IBA 01/2018 - 07/2007
2	N-(3-chlorophenyl)picolinamideIBA 08/2015 - 02/2012
2	Amphetamine (Amfetamine)FDA LinkGeneric 03/2015 - 07/2014
2	metabotropic glutamate receptor 3 (mGluR3)IBA 01/2015 - 07/2007
2	Reserpine (Serpasil)FDA Link 03/2013 - 11/2008
2	LigandsIBA 01/2010 - 12/2009
2	VU 0155041IBA 09/2009 - 11/2008
1	VU0453595IBA 01/2022
1	VU6019650IBA 01/2022
1	Antidepressive Agents (Antidepressants)IBA 11/2021
1	Neurotransmitter Agents (Neurotransmitter)IBA 08/2021
1	Muscarinic AntagonistsIBA 08/2021
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2021
1	VU0652957IBA 03/2019
1	Hydroxyl RadicalIBA 09/2018
1	AminesIBA 01/2018
1	Muscarinic M4 ReceptorIBA 01/2018
1	RNA (Ribonucleic Acid)IBA 01/2018
1	VU0467485IBA 02/2017
1	VU0476406IBA 01/2017
1	Clozapine (Clozaril)FDA LinkGeneric 03/2016
1	Hypnotics and Sedatives (Sedatives)IBA 03/2016
1	5- amino- 3,4- dimethyl- N- (4- ((trifluoromethyl)sulfonyl)benzyl)thieno(2,3- c)pyridazine- 6- carboxamideIBA 03/2016
1	VU0486321IBA 02/2016
1	5- methyl- N- (4- methylpyrimidin- 2- yl)- 4- (1H- pyrazol- 4- yl)thiazol- 2- amineIBA 01/2016
1	Proteins (Proteins, Gene)FDA Link 01/2016
1	Therapeutic UsesIBA 01/2016
1	Blood Proteins (Serum Proteins)IBA 11/2015
1	Dihydroxyphenylalanine (Dopa)IBA 08/2015
1	LSP1 2111IBA 08/2015
1	VU0409551IBA 06/2015
1	Exenatide (Byetta)FDA Link 12/2014
1	Cytochrome P-450 CYP3AIBA 12/2013
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 09/2013
1	Cocaine (Cocaine HCl)IBA 08/2013
1	VU0463841IBA 08/2013
1	SaltsIBA 03/2013
1	metabotropic glutamate receptor 8IBA 03/2013
1	ML253IBA 01/2013
1	Adenosine (Adenocard)FDA LinkGeneric 02/2012
1	2- (2- furanyl)- 7- (2- (4- (4- (2- methoxyethoxy)phenyl)- 1- piperazinyl)ethyl)- 7H- pyrazolo(4,3- e)(1,2,4)triazolo(1,5- c)pyrimidine- 5- amineIBA 02/2012
1	Oxidopamine (6 Hydroxydopamine)IBA 02/2012
1	AMPA Receptors (AMPA Receptor)IBA 12/2009
1	Pilocarpine (Ocusert)FDA LinkGeneric 08/2009
1	N- (3- oxo- 3- (4- (pyridin- 4- yl)piperazin- 1- yl)propyl)benzo(c)(1,2,5)thiadiazole- 4- sulfonamideIBA 08/2009
1	Cre recombinaseIBA 02/2008

Therapy/Procedure

3	Therapeutics 08/2021 - 06/2009
1	Drug Therapy (Chemotherapy) 03/2016